CONFERENCES

      International Symposium on Atherosclerosis

      ISA is an annual conference that explores the latest developments in atherosclerosis research, with topics ranging from pathophysiology to prevention. The conference is aimed at researchers, clinicians, and other professionals involved in the study and treatment of atherosclerosis, and provides a forum for sharing knowledge and collaborating on new approaches to preventing and treating cardiovascular disease.

      18th ISA Symposium 2018

      Date

      Jun 09, 2018 - Jun 12, 2018

      Location

      Toronto, Canada

      This symposium includes the research by PMI scientists on the changes in smoking-related diseases associated with clinical risk endpoints after switching to the tobacco heating systems.

      See related posters

      14th ISA Symposium 2006

      Date

      Jun 18, 2006 - Jun 22, 2006

      Location

      Rome, Italy

      This symposium includes the research by PMI scientists on the long-term exposure to cigarettes, focusing primarily on the development of atherosclerosis.

      See related posters

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.